opebacan

Opebacan is a recombinant fragment of human bactericidal/permeability-increasing protein (BPI), specifically a 21 kDa peptide corresponding to amino acids 1–193 of BPI. It is an injectable biologic drug with potential anti-infective and anti-inflammatory activity. Opebacan acts by neutralizing endotoxins, particularly lipopolysaccharides from Gram-negative bacteria, thereby reducing inflammation and infection risk in clinical settings characterized by neutropenia or compromised immune function. The drug has been investigated for use in conditions such as burns and burn infections, Crohn's disease, cardiovascular disorders, congenital anomalies, pediatric indications, wound infections, graft-versus-host disease following hematopoietic stem cell transplantation (HSCT), surgical wound infection, and radiation injuries. Its development was initially led by XOMA Royalty Corp., with clinical trials reaching up to Phase 3 for some indications[1][2][3][4][5].

Brand names

Neuprex

Other names

1-193-bactericidal/permeability-increasing protein (132-alanine) (human reduced)1-193-bactericidal/permeability-increasing protein (132-alanine) (human)bactericidal permeability-increasing protein opebacan